Research Keyword: psychotherapy

The collective lie in ketamine therapy: a call to realign clinical practice with neurobiology

mycolabadmin

This article argues that ketamine therapy is commonly misunderstood as a consciousness-expanding psychedelic when it actually works through a completely different biological mechanism. The real therapeutic benefit comes from the brain’s natural reorganization in the days after treatment, not from the altered states people experience during the session itself. The authors call for medical practitioners to stop emphasizing the dissociative experience and instead focus on helping patients build healthy thought patterns during the recovery period when the brain is most ready to form new connections.

Read More »

Anhedonia: Current and future treatments

mycolabadmin

Anhedonia is the inability to feel pleasure from activities, which is a significant problem affecting many people with depression and other psychiatric conditions. This review examined many different treatments for anhedonia including medications, brain stimulation techniques, and psychological therapies. The research shows that newer medications like vortioxetine and ketamine work better for anhedonia than older antidepressants, and combining multiple approaches including therapy and lifestyle changes gives the best results.

Read More »

Expanded access to psychedelic treatments: comparing American and Canadian policies

mycolabadmin

This article compares how the United States and Canada allow patients with serious health conditions like PTSD and depression to access experimental psychedelic treatments outside of clinical trials. Canada’s program has allowed over 200 patients to access psilocybin and MDMA treatments since 2022, while the US has only approved 50 patients for MDMA. The authors argue that Canada’s approach is more ethical and accessible, and suggest the US should streamline its process to help more patients who have failed conventional treatments.

Read More »

Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial

mycolabadmin

Researchers tested whether combining psilocybin therapy with mindfulness training could better treat depression and burnout in frontline healthcare workers than mindfulness training alone. Twenty-five doctors and nurses participated in the study, with some receiving mindfulness training combined with psilocybin therapy in a group setting, while others received mindfulness training only. After two weeks, those who received the combined treatment showed significantly greater improvements in depression symptoms and burnout, with no serious side effects reported. This suggests that psilocybin-assisted therapy combined with mindfulness training could be a promising treatment for depression and burnout among healthcare professionals.

Read More »

The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis

mycolabadmin

This research examined how different types of psychological support during psilocybin treatment affect depression outcomes. Researchers analyzed 10 clinical trials involving 515 patients with depression. They found that whether therapists used structured manuals or flexible approaches, or whether therapy was directive or non-directive, the depression improvement from psilocybin treatment was similar across all approaches.

Read More »

The development of psilocybin therapy for treatment-resistant depression: an update

mycolabadmin

Psilocybin, a compound found in certain mushrooms, is being studied as a potential treatment for severe depression that doesn’t respond to standard medications. In clinical trials, patients receiving psilocybin alongside psychological support showed significant improvement in depressive symptoms within days to weeks, with benefits lasting for months. Unlike daily antidepressant pills, psilocybin therapy involves one or more carefully supervised dosing sessions in a hospital setting with therapeutic support before and after. Larger studies are underway to confirm its effectiveness and safety before it could potentially become an approved treatment.

Read More »
Scroll to Top